Tsoukas et al., "Activation of Resting T Lymphocytes By Anti-CD3 (T3) Antibodies in the Absence of Monocytes", The Journal of Immunology, vol. 135, No. 3, Sep. 1985, pp. 1719-1723. |
Hogan et al., "Lymphokine-Activated and Natural Killer Cell Activity in Human Intestinal Mucosa", The Journal of Immunology, vol. 135, No. 3, Sep. 1985, pp. 1731-1738. |
P.M. Anderson et al., Cancer Immunol. Immunother., 1988, 27, 82, "Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2". |
P.M. Anderson et al., J. Immunol., 1989, 142, 1383, "Anti-CD3.sup.+ IL-2-Stimulated Murine Killer Cells in Vitro Generation and In Vivo Antitumor Activity". |
L.S. Davis et al., Cell Immunol., 1989, 118, 208, "T Cell Activation Induced by Anti-CD3 Antibodies Requires Prolonged Stimulation of Protein Kinase C". |
Dianzani et al., Eur. J. Immunol., 19: 1037 (1989), "CD8.sup.+ CD11b+ peripheral blood T lymphocytes contain lymphokine-activated killer cell precursors". |
Geller et al., J. Immunol., 146(10): 3280 (1991), "Generation of Lymphokine Activated Killer Activity in T Cells". |
T.D. Geppert et al., J. Clin. Invest., 1988, 81, 1497, "Activation of T Lymphocytes by Immobilized Monoclonal Antibodies to CD3". |
E.A. Grimm et al., J. Exp. Med., 1982, 155, 1823, "Lymphokine-Activated Killer Cells Phenomenon". |
M. Izquierdo et al., Clin. Exp. Immunol., 1988, 74, 300, "Selection T cell subset depletion with anti-CD4 and anti-CD8 intact ricin immunotoxins". |
C.M. Loeffler et al., Cancer Res., 51:2127 (1991), "Antitumor Effects of Interleukin 2 Liposomes and Anti-CD3-Stimulated T-Cells Against Murine MCA-38 Hepatic Metastasis". |
E. Lotzova et al., Nat. Immun. Cell Growth Regul., 1987, 8, 219, "Augmentation of Antileukemia Lytic Activity by OKT3 Monoclonal Antibody: Synergism of OKT3 and Interleukin-2". |
A.C. Ochoa et al., Cancer Res., 49: 963 (1989), "Lymphokine-activated Killer Activity in Long-Term Cultures with Anti-CD3 plus Interleukin 2: Identification and Isolation of Effector Subsets". |
A.C. Ochoa et al., J. Immunol., 1987, 138, 2728, "Long-Term Growth of Lymphokine-Activated Killer (LAK) Cells: Role of Anti-CD3, .beta.-IL 1, Interferon-.gamma. and -.beta.". |
L.E. Samelson et al., Proc. Natl. Acad. Sci. USA, 87: 4358 (1990), "Association of the fyn protein-tyrosine kinase with the T-cell antigen receptor". |
R. Schwab et al., J. Immunol., 1985, 135, 1714, "Requirements for T-Cell Activation by OKT3 Monoclonal Antibody: Role of Modulation of T3 Molecules and Interleukin". |
S. Shu et al., J. Immunol., 1985, 135, 2895, "Adoptive Immunotherapy of a Newly Induced Sarcoma: Immunlogic Characteristics of Effector Cells". |
Smyth, J. Exp. Med, 171: 1269 (1990),"Interleukin 2 Induction of Pure-Forming Protein Gene Expression in Human Peripheral Blood CD8.sup.+ T Cells". |
Smyth, J. Immunol., 148: 3289 (1991), "Regulation of Lymphokine-Activated Killer Activity and Pore-forming Protein Gene Expression in Huan Peripheral Blood CD8.sup.+ T Lymphocytes". |
C.-C. Ting et al., Immunol. Invest., 1990, 19, 347, "Anti-CD3 Antibody-Induced Activated Killer Cells Subsets of Killer Cells that Mediate Fast or Slow Lytic Reactions". |
M. C. Turco et al., Blood, 1989, 74, 1651, Proliferative Pathways in CD1.sup.- CD3.sup.+ CD4.sup.+ CD8.sup.+ T Prolymphocytic Leukemic Cells: Analysis with Monoclonal Antibodies and Cytokines. |
R. J. van de Griend et al., J. Immunol., 1987, 138, 1627, "Lysis of Tumor Cells by CD3.sup.+ 4.sup.- 8.sup.- 16.sup.+ T Cell Receptor .alpha..beta.-Clones, Regulated Via CD3 and CD16 Activation Sites, Recombinant Interleukin 2, and Interferon .beta.". |
W. H. West et al., J. Immunol., 1977, 118, 355, "Natural Cytotoxic Reactivity of Human Lymphocytes Against a Myeloid Cell Line: Characterization of Effector Cells". |
Ochas et al., FASEB Journal, 3(3)A: 826 (abstract) (1989), "T Cels Can Develop High Lak Activity: Possible Regulatory Circuits". |
Lotze et al., Cancer Res., 41: 4420 (1981), "Lysis of Fresh and Cultured Autologous Tumor by Human Lymphocytes Cultured in T-Cell Growth Factor". |
Balldegrun et al., Cancer Res., 48: 206 (1988), "Interleukin 2 Expanded Tumor-infiltrating Lymphocytes in Human Renal Cell Cancer: Isolation, Characterization, and Antitumor Activity". |
Maghazachi et al., J. Immunol., 141: 4039 (1988), "Influence of T Cells on the Expression of Lymphokine-Activated Killer Cell Activity and In Vivo Tissue Distribution". |
Damle et al., J. Exp. Med., 158: 159 (1983), "Immunoregulatory T Cell Circuits in Man". |
Lewis et al., PNAS, USA, 85: 9743 (1988), "Restricted production of interleukin 4 by activated human T cells". |
Halvorsen et al., Scand J. Immunol. 27, 555-563, 1988, "Role of Accessory Cells in the Activation of Pure T Cells via the T Cell Receptor-CD3 Complex or with Phytohaemaggloutnin". |
Halvorsen et al., Scand J. Immunol. 26, 197-205, 1987, "Activation of Resting, Pure CD4.sup.+, and CD8.sup.+ Cells via CD3". |
Curti et al. J. Clin. Oncol. 11:652-660 (1993). |
Whiteside et al. Cancer Immunol Immunother 39: 14-22 (1994). |
Strome et al. J. Hematotherpy 2:63-73 (1993). |
Michih Immunol Ser 61: 293-309 (1994). |
Votze Cell Transplantation 2: 33-47 (1993). |
Lindemann et al. Blut 59: 375-384 (1989). |
Teichmann et al. Nat Immun 11: 117-132 (1992). |
Ochos et al. Cancer Research 49: 963-968 (1989). |
Bieva et al. Exp Hematol 17: 914-920 (1989). |
Smyth, et al.; Journal of Experimental Medicine, vol. 171, pp. 1269-1281; Apr. 1990. |
Ochoa, et al. "Long-Term Growth of Lymphokine-Activated Killer (LAK) Cell 59 Role of Anti-CD3, B-IL9, Interferon-.gamma. and -.beta." The Journal of Immunology, vol. 138, No. 8, pp. 2728-2733 1987. |
Ochoa, et al. T Cells Can Develop High LAK Activity: Possible Regulatory Circuits FASEB Journal, vol. 3, No. 3 (Pt. 1), A826 (Abstract) 1989. |
Geller, et al. Generation of Lymphokine-Activated Killer Activity in T Cells --Possible Regulatory Circuits The Journal of Immunology, vol. 146, No. 10, pp. 3280-3288 1991. |